Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
24.05
+0.29 (1.22%)
At close: Jul 21, 2026, 4:00 PM EDT
24.05
0.00 (0.00%)
After-hours: Jul 21, 2026, 4:49 PM EDT
Zymeworks Revenue
Zymeworks had revenue of $2.41M in the quarter ending March 31, 2026, a decrease of -91.12%. This brings the company's revenue in the last twelve months to $81.26M, down -12.98% year-over-year. In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth.
Revenue (ttm)
$81.26M
Revenue Growth
-12.98%
P/S Ratio
21.19
Revenue / Employee
$334,416
Employees
243
Market Cap
1.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Sarepta Therapeutics | 2.18B |
| Immunocore Holdings | 412.81M |
| AnaptysBio | 232.39M |
| Ascentage Pharma Group International | 82.08M |
| Stoke Therapeutics | 32.08M |
| Precigen | 31.60M |
| Generate Biomedicines | 30.30M |
ZYME News
- 3 hours ago - Zymeworks management to meet with B. Riley - TheFly
- 5 days ago - Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - GlobeNewsWire
- 14 days ago - Zymeworks price target raised to $31 from $28 at Truist - TheFly
- 21 days ago - Zymeworks price target raised to $37 from $34 at Wells Fargo - TheFly
- 21 days ago - Zymeworks price target raised to $37 from $35 at Citi - TheFly
- 22 days ago - Zymeworks Transcript: M&A announcement - Transcripts
- 22 days ago - Zymeworks Press release: M&A announcement - Filings
- 22 days ago - Zymeworks Slides: M&A announcement - Filings